肝硬化患者病情与小肠细菌过度生长变化关系探讨

doi:10.3969/j.issn.1672-5069.2016.03.014

摘要/Abstract

摘要： 目的探讨小肠细菌过度生长（SIBO）与肝硬化病情严重程度的关系及小肠细菌生长与降钙素原、胆红素、血浆白蛋白、球蛋白的相关性。方法纳入本科收治的47例肝硬化患者和15名健康志愿者。受试者接受乳果糖氢呼气试验（LHBT），检测小肠细菌过度生长情况，使用全自动生化分析仪测定生化指标。采用自评表形式对肝硬化组患者症状进行评估。结果在15名健康志愿者中检出1例（6.6%）伴小肠细菌过度生长，而在47例肝硬化患者中检出22例（46.8%）患者伴小肠细菌过度生长，显著高于正常人（P＜0.01）；肝硬化患者LHBT集值为（157.81±98.32）ppm，显著高于健康人[(38.87±16.05）ppm，P＜0.01],血清胆红素为（93.31±55.15）μmol/L，显著高于健康人[（14.78±8.12）μmol/L,P＜0.01]，白蛋白为（31.74±10.37）g/L，显著低于健康人[(43.90±7.63) g/L， P＜0.01]，球蛋白为（39.09±5.07）g/L，高于健康人[(35.94±2.31) g/L，P＞0.05]，降钙素原为（0.10±0.07）ng/ml，显著高于健康人[(0.03±0.01) ng/ml，P＜0.01]；降钙素原、胆红素、血浆白蛋白、球蛋白与LHBT集值具有相关性（r=0.895、P＜0.005，r=0.907、P＜0.005，r=-0.810、P＜0.005，r=0.755，P＜0.005）。结论肝硬化患者SIBO发生率随肝功能损害程度的加重而增加，肝硬化SIBO患者腹胀及食欲不振更明显。降钙素原、胆红素和球蛋白分别与SIBO呈正相关，血浆白蛋白与SIBO呈负相关。

关键词: 肝硬化, 小肠细菌过度生长, 氢呼气集值, 胃肠道症状评估

Abstract: Obiective To determine the prevalence of small intestinal bacterial overgrowth（SIBO） in cirrhotic patients，and its correlation to severity of cirrhosis. Methods 47 patients with cirrhosis were selected as observation group，and 15 healthy volunteers were selected as control group. The gastrointestinal symptom of patients were evaluated by a guidance for clinical rational. The data were statistical analysis using SPSS17.0. Results In 47 patients with liver cirrhosis，22 patients（46.8%） were SIBO positive.While in 15 healthy persons in control group，only 1 case（6.6%，P<0.01） was SIBO positive；the LHBT level in patients with cirrhosis was （157.81±98.32） ppm，significantly higher than in the control group[（38.87±16.05） ppm，P＜0.01]，serum bilirubin levels were（93.31±55.15） μmol/L，significantly higher than that in the control group[（14.78±8.12） μmol/L，P＜0.01]，plasma albumin were（31.74±10.37） g/L，significantly lower than that in the control group [（43.90±7.63） g/L，P＜0.01]，globulin were（39.09±5.07） g/L，higher than that in the control group[（35.94±2.31） g/L，P＞0.05]，procalcitonin were（0.10±0.07） ng/ml，significantly higher than that in the control group[（0.03±0.01） ng/ml，P＜0.01]；plasma procalcitonin，bilirubin，globulin and albumin were respectively correlated to SIBO（r=0.895，P＜0.005；r=0.907，P＜0.005；r=0.755，P＜0.005；r=-0.810，P＜0.005）. Conclusions SIBO is prevalent in patients with liver cirrhosis. The cirrhotic patients with SIBO are more easily bloating and loss of appetite.

Key words: Liver cirrhosis, Small intestinal bacteria overgrowth, Hydrogen breath set-value, Gastrointestinal symptom rating scale.

魏新朋，韩际奥，高晓，杨丽，马英杰. 肝硬化患者病情与小肠细菌过度生长变化关系探讨[J]. 实用肝脏病杂志, 2016, 19(3): 310-313.

Wei Xinpeng,Han Ji＇ao,Gao Xiao,et al.. Small intestinal bacterial overgrowth in patients with liver cirrhosis[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(3): 310-313.

参考文献

[1] 曹彬，丰义宽，李国庆. 肝硬化患者小肠细菌过度生长与轻微肝性脑病发生的相关性研究. 实用肝脏病杂志，2008，11（1）：50-52.
[2] Chang CS，Chen GH，Lien HC，et al. Small intestine dysmotility and bacterial overgrowth in cirrhotic patients with spontaneous bacterial peritonitis. Hepatology，1998，28（5）:1187-1190.
[3] Bures J，Cyrany J，Kohoutova D，et al. Small intestinal bacterial overgrowth syndrome. World J Gastroenterol，2010，16（24）：2978-2990.
[4] 中华医学会肝病学分会，中华医学会感染病学分会. 慢性乙型肝炎防治指南. 实用肝脏病杂志，2011，14（2）:81-89.
[5] Pande CA，Kumar SK. Small-intestinal bacterial overgrowth in cirrhosis is related to the severity of liver disease. Aliment Pharmacol Ther，2009. 29（12）:1273-1281.
[6] Lombardo L，Foti M，Ruggia O，et al. Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy. Clin Gastroenterol Hepatol，2010，8（6）：504－508.
[7] Jacobs C，Coss Adame E，Attaluri A，et.al. Dysmotility and proton pump inhibitor use are independent risk factor for small intestinal bacterial and/or fungal overgrowth.Aliment Pharmacol Ther 2013，37:1103-1111.
[8] Pardo A，Bartoli R，Lorenzo-Zuniga V，et al. Effect of cisapride on intestinal bacterial overgrowth and bacterial translocation in cirrhosis. Hepatology，2000，31（4）:858-863.
[9] 逢作祥，李晓东，吕小军，等. 小肠细菌过度生长与肝硬化的关系探讨. 实用肝脏病杂志，2008，11（5）：327－328.
[10] 周红宇，周国华，冷明芳，等. 肝硬化小肠细菌过度生长情况分析.疑难病杂志，2011，10（3）:185-187.
[11] Morencos FC，delas Heras Castano G，Martin Ramos L，et al. Small bowel bacterial overgrowth in patients with alcoholic cirrhosis. Dig Dis Sci，1995，40:1252-1256.
[12] Yang CY，Chang CS，Chen GH. Small-intestinal bacterial overgrowth in patients with liver cirrhosis，diagnosed with glucose H2 or CH4 breath tests. Scand J Gastroenterol，1998，33:867-871.
[13] Wilberg S，Pieramico 0，Malfertheiner P．The H2-lactulose breath test in the diagnosis of intestinal transittime．Leber Magen Darm，1990，20（3）：129-137．
[14] Chen CY，Lu CL，Chang FY，et a1．Delayed gastrointestinal transit in patients with hepatocellular carcinoma．J Gastroenterol Hepatol，2002，17（12）：1254-1269.
[15] 曹曙光，吴昊，徐昌隆，等. 肝硬化患者小肠细菌过度生长在肠道气体产生中的作用. 中华肝脏病杂志，2010，18（11）:864-865.
[16] 李山林，刘学进，周洪涛. 肝硬化与小肠细菌过度生长的关系.中国当代医药，2014，21（35）:58-60.
[17] Morgenthaler NG，Struck J，Chancerelle Y，et a1．Production of procalcitonin（PCT）in non-thyroidal tissue after LPS injection．Horm Metab Res，2003，35（5）：290-295.
[18] The Organize of the Expert Consensus on the Clinical Application of Procalcitonin in Emergency．The expert consensus on the clinical application of procalcitonin in emergency．Chin J Emerg Med，2012，21（9）：944-951.
[19] Bota DP，Van Nuffelen M，Zakariah AN，et a1．Serum levels of C-reactive protein and procalcitonin in critically ill patients with cirrhosis of the liver．J Lab C1iIl Med，2005，146（6）：347-351．
[20] Lesinska M，Hartleb M，Gutkowski K，et a1．Procalcitonin and macrophage inflammatory protein-1 beta（MIP-1β）in serum and peritoneal fluid of patients with decompensated cirrhosis and spontaneous bacterial peritonitis．Adv Med Sci，2014，59（1）：52-56．
[21] Connert S，Stremmel W，Elsing C．Procalcitonin is a valid marker of infection in decompensated cirrhosis．Z Gastroenterol，2003，4l（2）：165-170.